IP Library Granted Patent US 8,497,372
Granted Patent B2
US 8,497,372 · App. 13/487,434 · Granted Jul 30, 2013

Use of substituted quinazoline compounds in treating age-related macular degeneration

Inventors: Wei-Guo Su (Shanghai, CN); Weihan Zhang (Shanghai, CN); Xiaoqiang Yan (Shanghai, CN); Yumin Cui (Shanghai, CN); Yongxin Ren (Shanghai, CN); Jifeng Duan (Shanghai, CN)
Assignee: Hutchison Medipharma Enterprises Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,497,372
App. No.
13/487,434
Granted
Jul 30, 2013
Kind
B2
Abstract

Quinazoline derivatives of the following formula: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , X, and Z are defined herein. It also discloses a method of treating an angiogenesis-related disorder with one of these compounds.

Claims (20)

1. A method of treating age-related macular degeneration mediated by kinase insert domain receptor activity comprising

administering to a subject in need thereof an effective amount of a compound of the following formula:

wherein

each of R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , R 9 , and R 10 , independently, is H, halo, amino, hydroxy, alkyl, alkenyl, alkynyl, heterocycloalkyl, alkoxy, alkylthio, carboxy, alkoxycarbonyl, carbonylamino, or sulfonylamino;

R 6 is alkyl;

R 7 is alkoxycarbonyl, aminocarbonyl, or aminosulfonyl;

X is O; and

Z is N;

wherein each of alkyl, alkenyl, alkynyl, heterocycloalkyl, and alkoxy is optionally substituted with at least one substituent chosen from halo, hydroxy, amino, cyano, nitro, mercapto, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, carbamido, carbamoyl, thioureido, thiocyanato, sulfonamido, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

2. The method of claim 1 , wherein R 7 is —C(O)NR a R b , each of R a and R b , independently, being H, alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, or R a and R b , together with the nitrogen atom to which they are attached, represent a 3-8 membered ring containing 1-3 heteroatoms;

wherein each of alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl for R a and R b is optionally substituted with at least one substituent chosen from halo, hydroxy, amino, cyano, nitro, mercapto, alkoxycarbonyl, amido, carboxy, alkanesulfonyl, alkylcarbonyl, carbamido, carbamoyl, thioureido, thiocyanato, sulfonamido, alkyl, alkenyl, alkynyl, alkoxy, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl.

3. The method of claim 2 , wherein each of R a and R b , independently, is H, optionally substituted alkyl, or optionally substituted cycloalkyl.

4. The method of claim 3 , wherein R 6 is optionally substituted methyl.

5. The method of claim 3 , wherein R a is H and R b is optionally substituted methyl.

6. The method of claim 3 , wherein each of R 3 and R 4 is methoxy.

7. The method of claim 1 , wherein R 6 is optionally substituted methyl.

8. The method of claim 7 , wherein R 6 is methyl.

9. The method of claim 1 , wherein each of R 3 and R 4 is optionally substituted alkoxy.

10. A method of treating age-related macular degeneration mediated by kinase insert domain receptor activity comprising

administering to a subject in need thereof an effective amount of a compound chosen from

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2023
From: HUTCHMED HOLDINGS ENTERPRISES LIMITED
To: HUTCHMED LIMITED
Reel/Frame 064075/0996 →
CHANGE OF NAME Recorded Nov 3, 2022
From: HUTCHISON MEDIPHARMA ENTERPRISES LIMITED
To: HUTCHMED HOLDINGS ENTERPRISES LIMITED
Reel/Frame 061880/0367 →
Continuity (3)
Continuation 12893872 · Sep 29, 2010
Division 12118019 · May 9, 2008
Related Publication 20120238572A1 · Sep 20, 2012